Global Embryo Selection Tool Market Growth (Status and Outlook) 2025-2031

The global Embryo Selection Tool market size is predicted to grow from US$ 37.3 million in 2025 to US$ 49.2 million in 2031; it is expected to grow at a CAGR of 4.7% from 2025 to 2031.

An Embryo Selection Tool is a technology-driven system used in in vitro fertilization (IVF) to help embryologists and fertility specialists identify the best-quality embryos for implantation. These tools use AI, time-lapse imaging, and genetic screening to improve pregnancy success rates and reduce subjectivity in the embryo grading process.

United States market for Embryo Selection Tool is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Embryo Selection Tool is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Embryo Selection Tool is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Embryo Selection Tool players cover Vitrolife, Genea BIOMEDX, MIM Fertility, Alife Health, Fairtility, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Embryo Selection Tool Industry Forecast” looks at past sales and reviews total world Embryo Selection Tool sales in 2024, providing a comprehensive analysis by region and market sector of projected Embryo Selection Tool sales for 2025 through 2031. With Embryo Selection Tool sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Embryo Selection Tool industry.

This Insight Report provides a comprehensive analysis of the global Embryo Selection Tool landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Embryo Selection Tool portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Embryo Selection Tool market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Embryo Selection Tool and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Embryo Selection Tool.

This report presents a comprehensive overview, market shares, and growth opportunities of Embryo Selection Tool market by product type, application, key players and key regions and countries.

Segmentation by Type:
Web-based
Cloud-based

Segmentation by Application:
Hospital
Clinic
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Vitrolife
Genea BIOMEDX
MIM Fertility
Alife Health
Fairtility
ASTEC CO., Ltd
Care Fertility
Cycle Clarity
KritiKal Solutions
ImVitro

Please note: The report will take approximately 2 business days to prepare and deliver.